Covidien Announces R&D Center in China
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the creation of its flagship research and development (R&D) center for China, which will be based in Shanghai.
The center, which will be fully functional by July 2012, will house two of Covidien's emerging market R&D organizations:
Tailored Products – will identify and develop products that are customized to meet the needs of China and other countries in the emerging markets
Breakthrough Platforms – will utilize the unique skill sets and expertise of employees in Asia to create and develop new medical device technologies.
“The establishment of this R&D facility is a first for Covidien in China,” said Dr. Dong Wu, Vice President, China R&D, Covidien. “We will be undertaking a range of cutting-edge activities that will create innovative products to help physicians improve the health of the people of China and of other markets worldwide.”
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.